Agreement with CIBIT

APTA Therapeutics is pleased to announce that it has entered into an agreement with Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT) to support an Investigator Initiated Trial with rovunaptabin in patients with long COVID.

APTA Therapeutics is pleased to announce that it has entered into an agreement with Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT) to support an Investigator Initiated Trial with rovunaptabin in patients with long COVID.
With its expertise in translational clinical research and quantitative measurements of the autonomic nervous system, CIBIT is well positioned to contribute to advancing the clinical development of rovunaptabin in an indication of high unmet medical need affecting millions of patients worldwide.

BACK TO NEWS ROOM